Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Equinix Inc
Latest stored price
Stem Cell Innovations, Inc.
Decision snapshot
EQIX stock price vs Stem Cell Innovations, Inc.: inconclusive
Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Price gap
N/A
Coverage
Low · 40%
Free account · revisit it from your workspace
Quick read
Decision-focused synthesis of expected stock prices combining relative peer multiples and intrinsic models.
Current Price
EQIX
Implied Fair Value
EQIX
via P/E multiple
The P/E multiple calculation requires positive values for all inputs. Missing: EPS (TTM), Stem Cell Innovations, Inc. P/E.
Latest stored price
Metric-by-metric
Filter, sort, and scan where each company leads, where gaps are small, and where comparisons are not meaningful.
| Metric | EQIX | Stem Cell Innovations, Inc. | Spread |
|---|---|---|---|
Revenue growth (YoY) YoY from latest annual filings | N/M | N/M | Insufficient data No additional context |
Gross margin | N/M | N/M | Insufficient data Pricing power |
EBITDA margin | N/M | N/M | Insufficient data Operating leverage |
EV/Revenue | N/M | N/M | Insufficient data No additional context |
P/E | N/M | N/M | Not comparable Not comparable |
Net debt / EBITDA | N/M | N/M | Insufficient data Lower leverage |
Statements
Core income statement and balance sheet metrics aligned to the reporting windows.
| Metric | EQIX | Delta vs Stem Cell Innovations, Inc. | Stem Cell Innovations, Inc. |
|---|---|---|---|
| Revenue | — | N/A | — |
| Gross profit | — | N/A | — |
| Operating income | — | N/A | — |
| EBITDA | — | N/A | — |
| Net income | — | N/A | — |
| EPS | — | N/A | — |
| Revenue growth | — | N/A | — |
| Gross margin | — | N/A | — |
| Operating margin | — | N/A | — |
| EBITDA margin | — | N/A | — |
| Net margin | — | N/A | — |
Price framework
Market cap + debt - cash, shown for the current pair and benchmark median context.
Price framework
Baseline discounted cash flow model estimating total intrinsic firm value first, then bridging to an implied stock price per share.
Risk control
Financial health checks to separate durable balance sheets from potential value traps.
Comparable set
Place both companies in context relative to a wider comparable universe.
LLM-powered Synthesis
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
